Our results, supported by the literature, propose BRCA1 promoter hypermethylation as a potential useful biomarker for breast tumor aggressiveness, as well as an early biomarker for both BBLs at risk to progressing into cancer and NATs harboring the tumors at risk of recurrence. Here, BRCA1 is linked to cancer.